Dr. Raymond S. Lance , MD
Urology โข Spokane, WA
1401 E Trent Ave Ste 200
Spokane, WA 992022902
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
NPI assigned on May 19, 2006; this date does not establish years in practice.
-
Published CMS data list 5,560 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- J0897 โ Injection, denosumab, 1 mg: 2,340 service units.
- G2211 โ Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's: 747 service units.
- 99214 โ Established patient outpatient office visit: 407 service units.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPTยฎ only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 34 records in the table ยท Guide: How to read Medicare Part B data
-
Published CMS data list 2,334 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers โ by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Finasteride โ 517 prescription fills, including refills.
- Tamsulosin Hcl โ 374 prescription fills, including refills.
- Orgovyx (Relugolix) โ 242 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers โ by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 27 records in the table ยท Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 95% of clinicians listed under Urology in Spokane, WA (2024, 11 clinicians with data). Median for this group: 1,638. Middle half: 1,062 to 2,959.
More Medicare Part B services than 90% of clinicians listed under Urology in Washington (2024, 191 clinicians with data). Median for this group: 802. Middle half: 338 to 1,756.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 9,185 in 2020 to 5,560 in 2024.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2020โ2024.
Practice Location & Contact Primary Location
1401 E Trent Ave Ste 200
Spokane, WA 992022902
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
CMS Doctors and Clinicians lists 1 group name: Spokane Urology Pllc. See the list
Source: CMS Doctors and Clinicians National Downloadable File, release date unavailable.
Listings do not confirm current availability, employment or a shared ownership network.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
Uniformed Services Uhs Fe Hebert School Of Med
1991
What Public CMS Data Show
Urology: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
630 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider, 2024.
Medicare-allowed amount
About $390,311 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024.
Paid by Medicare
About $297,527 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024.
30-day fills
3,274 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$3,573,473 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers โ by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $25,919.97 across 102 records.
By nature of payment (3 largest of 5)
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program: $18,731.25 across 6 records.
- Travel and Lodging: $2,586.98 across 7 records.
- Food and Beverage: $2,521.75 across 85 records.
Reporting-company totals (3 largest of 24)
- Janssen Pharmaceuticals, Inc: $22,213.15 across 34 records.
- Bayer Healthcare Pharmaceuticals Inc.: $1,970.53 across 4 records.
- Astellas Pharma US Inc: $462.29 across 12 records.
Research and ownership records are not included in these totals; they are in the table below.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
35 years (graduated 1991)
CMS Doctors and Clinicians data list 1991 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2006
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, โDoes your provider accept Medicare as full payment?โ
Telehealth (some services)
Recent Medicare claims show this clinician provided some services by telehealth, such as a video or phone visit.
You may be able to have some visits without going to the office. Ask which visits can be done by telehealth.
What this does not show: Telehealth (some services)
It does not mean all services are offered by telehealth, or that telehealth is covered by your plan.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Lance has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Lance as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Spokane and Washington
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 95% of clinicians listed under Urology in Spokane, WA (2024, 11 clinicians with data). Median for this group: 1,638. Middle half: 1,062 to 2,959.
More Medicare Part B services than 90% of clinicians listed under Urology in Washington (2024, 191 clinicians with data). Median for this group: 802. Middle half: 338 to 1,756.
Medicare-allowed amount
A higher Medicare-allowed amount than 95% of clinicians listed under Urology in Spokane, WA (2024, 11 clinicians with data). Median for this group: $157,823. Middle half: $97,059 to $201,357.
A higher Medicare-allowed amount than 95% of clinicians listed under Urology in Washington (2024, 191 clinicians with data). Median for this group: $83,512. Middle half: $34,252 to $154,605.
Paid by Medicare
A higher Medicare payment amount than 95% of clinicians listed under Urology in Spokane, WA (2024, 11 clinicians with data). Median for this group: $117,263. Middle half: $72,137 to $153,080.
A higher Medicare payment amount than 95% of clinicians listed under Urology in Washington (2024, 191 clinicians with data). Median for this group: $61,217. Middle half: $24,379 to $113,430.
Medicare Part D prescriptions
More Part D prescriptions than 95% of clinicians listed under Urology in Spokane, WA (2024, 12 clinicians with data). Median for this group: 941. Middle half: 765 to 1,160.
More Part D prescriptions than 95% of clinicians listed under Urology in Washington (2024, 225 clinicians with data). Median for this group: 732. Middle half: 221 to 1,224.
Part D drug cost
A higher Part D drug cost than 95% of clinicians listed under Urology in Spokane, WA (2024, 12 clinicians with data). Median for this group: $291,069. Middle half: $59,623 to $489,309.
A higher Part D drug cost than 95% of clinicians listed under Urology in Washington (2024, 225 clinicians with data). Median for this group: $40,788. Middle half: $9,435 to $122,211.
20 active clinicians are listed under Urology with a practice address in Spokane, WA (335 in Washington).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Spokane
30% of these 20 clinicians have the CMS telehealth indicator.
50% of these 20 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services decreased 39% from 9,185 in 2020 to 5,560 in 2024.
- 2020: 9,185
- 2021: 8,078
- 2022: 4,458
- 2023: 3,407
- 2024: 5,560
-
Medicare-allowed amount
Medicare-allowed amount decreased 13% from $446,686 in 2020 to $390,311 in 2024.
- 2020: $446,686
- 2021: $385,700
- 2022: $223,516
- 2023: $279,847
- 2024: $390,311
-
Paid by Medicare
Paid by Medicare decreased 14% from $345,680 in 2020 to $297,527 in 2024.
- 2020: $345,680
- 2021: $295,556
- 2022: $168,525
- 2023: $214,370
- 2024: $297,527
-
Medicare Part D prescriptions
Medicare Part D prescriptions increased 51% from 1,543 in 2020 to 2,334 in 2024.
- 2020: 1,543
- 2021: 1,704
- 2022: 1,573
- 2023: 1,506
- 2024: 2,334
-
30-day fills
30-day fills increased 50% from 2,185 in 2020 to 3,274 in 2024.
- 2020: 2,185
- 2021: 2,501
- 2022: 2,411
- 2023: 2,275
- 2024: 3,274
-
Part D drug cost
Part D drug cost increased 29% from $2,779,193 in 2020 to $3,573,473 in 2024.
- 2020: $2,779,193
- 2021: $3,631,488
- 2022: $1,302,680
- 2023: $1,318,772
- 2024: $3,573,473
-
Industry payments (Open Payments)
Industry payments (Open Payments) increased 110% from $12,560.72 in 2021 to $26,323.76 in 2025.
- 2021: $12,560.72
- 2022: $31,390.43
- 2023: $21,584.17
- 2024: $38,801.93
- 2025: $26,323.76
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo ยท Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 โ December 31, 2025): 103 records totaling $26,323.76.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
RYBREVANT | General | $4,162.50 |
| Janssen Pharmaceuticals, Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
RYBREVANT | General | $4,162.50 |
| Janssen Pharmaceuticals, Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
RYBREVANT | General | $4,162.50 |
| Janssen Pharmaceuticals, Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
RYBREVANT | General | $3,607.50 |
| Janssen Pharmaceuticals, Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
RYBREVANT | General | $2,081.25 |
| Bayer Healthcare Pharmaceuticals Inc. |
Consulting Fee
Cash or cash equivalent
|
Nubeqa | General | $1,816.00 |
| Janssen Pharmaceuticals, Inc |
Travel and Lodging
In-kind items and services
|
RYBREVANT | General | $629.77 |
| Janssen Pharmaceuticals, Inc |
Travel and Lodging
Cash or cash equivalent
|
RYBREVANT | General | $564.90 |
| Janssen Pharmaceuticals, Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
RYBREVANT | General | $555.00 |
| Janssen Pharmaceuticals, Inc |
Travel and Lodging
In-kind items and services
|
RYBREVANT | General | $432.72 |
| Dendreon Pharmaceuticals LLC |
General
Cash or cash equivalent
|
PROVENGE | Research | $403.79 |
| Janssen Pharmaceuticals, Inc |
Travel and Lodging
In-kind items and services
|
RYBREVANT | General | $387.89 |
| Janssen Pharmaceuticals, Inc |
Travel and Lodging
In-kind items and services
|
RYBREVANT | General | $317.43 |
| Janssen Pharmaceuticals, Inc |
Travel and Lodging
In-kind items and services
|
RYBREVANT | General | $248.77 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
ERLEADA | General | $156.13 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
RYBREVANT | General | $125.00 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
RYBREVANT | General | $124.99 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
RYBREVANT | General | $120.24 |
| Bayer Healthcare Pharmaceuticals Inc. |
Food and Beverage
In-kind items and services
|
Nubeqa | General | $102.19 |
| Astellas Pharma US Inc |
Education
In-kind items and services
|
โ | General | $99.99 |
| Astellas Pharma US Inc |
Education
In-kind items and services
|
โ | General | $96.00 |
| BLUEWIND MEDICAL |
Food and Beverage
In-kind items and services
|
REVI | General | $81.54 |
| Janssen Pharmaceuticals, Inc |
Food and Beverage
In-kind items and services
|
ERLEADA | General | $78.50 |
| Boston Scientific Corporation |
Food and Beverage
In-kind items and services
|
Axonics | General | $78.32 |
| Astellas Pharma US Inc |
Education
In-kind items and services
|
โ | General | $68.00 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPTยฎ is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016โ2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners โ by Provider and Service data, 2017โ2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
J0897
Injection, denosumab, 1 mg
|
2,340 | 13 | $33.20 | $25.76 |
|
G2211
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
|
747 | 466 | $45.00 | $16.14 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
407 | 286 | $242.00 | $126.61 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
384 | 273 | $167.00 | $90.14 |
|
J9217
Leuprolide acetate (for depot suspension), 7.5 mg
|
172 | 24 | $385.70 | $174.00 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
143 | 143 | $348.00 | $163.99 |
|
36415
Insertion of needle into vein for collection of blood sample
|
140 | 119 | $21.00 | $8.59 |
|
J3315
Injection, triptorelin pamoate, 3.75 mg
|
117 | 20 | $1116.94 | $445.52 |
|
81002
Urinalysis, manual test
|
109 | 93 | $33.00 | $3.38 |
|
76872
Ultrasound scan of pelvic region through rectum
|
93 | 91 | $160.00 | $31.39 |
|
52000
Diagnostic exam of bladder and urethra using an endoscope
|
83 | 67 | $513.00 | $236.80 |
|
99490
Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month
|
71 | 25 | $63.43 | $62.43 |
|
55706
Needle biopsy of prostate gland using image guidance
|
69 | 69 | $825.00 | $361.24 |
|
96372
Injection of drug or substance under skin or into muscle
|
67 | 53 | $88.00 | $14.12 |
|
96402
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
|
65 | 38 | $101.00 | $35.19 |
|
J3260
Injection, tobramycin sulfate, up to 80 mg
|
53 | 18 | $8.15 | $2.57 |
|
74420
Imaging of urinary tract following injection of a contrast agent
|
52 | 37 | $54.00 | $23.73 |
|
G0103
Prostate cancer screening; prostate specific antigen test (psa)
|
50 | 50 | $75.00 | $18.92 |
|
J1580
Injection, garamycin, gentamicin, up to 80 mg
|
43 | 15 | $5.16 | $2.44 |
|
76872
Ultrasound scan of pelvic region through rectum
|
38 | 38 | $243.82 | $136.18 |
|
99439
Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month
|
37 | 21 | $48.69 | $47.91 |
|
52332
Insertion of stent in ureter using an endoscope
|
31 | 21 | $425.81 | $139.56 |
|
55700
Biopsy of prostate gland
|
31 | 31 | $618.00 | $236.68 |
|
51798
Ultrasound measurement of bladder capacity after voiding
|
29 | 27 | $50.00 | $11.50 |
|
52000
Diagnostic exam of bladder and urethra using an endoscope
|
29 | 27 | $300.00 | $76.55 |
(top 25 shown)
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Finasteride | Finasteride | 517 | 28,084 | $4,324.76 | 124 |
| Tamsulosin Hcl | Tamsulosin Hcl | 374 | 19,145 | $3,568.07 | 106 |
| Orgovyx | Relugolix | 242 | 7,256 | $632,241.46 | 39 |
| Tramadol Hcl | Tramadol Hcl | 146 | 452 | $241.29 | 123 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 146 | 2,364 | $833.70 | 112 |
| Nubeqa | Darolutamide | 120 | 3,780 | $1,671,028.82 | 16 |
| Levofloxacin | Levofloxacin | 111 | 633 | $385.83 | 101 |
| Silodosin | Silodosin | 105 | 4,110 | $7,040.94 | 23 |
| Erleada | Apalutamide | 58 | 1,740 | $842,306.11 | 12 |
| Bicalutamide | Bicalutamide | 56 | 3,360 | $1,677.37 | 16 |
| Imipramine Hcl | Imipramine Hcl | 53 | 1,770 | $818.43 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 191 | $312.88 | 44 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 42 | 2,061 | $596.25 | 14 |
| Abiraterone Acetate | Abiraterone Acetate | 39 | 1,350 | $40,214.00 | โ |
| Potassium Citrate Er | Potassium Citrate | 38 | 1,410 | $3,419.90 | โ |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | 930 | $294.81 | 13 |
| Prednisone | Prednisone | 27 | 930 | $118.60 | โ |
| Xtandi | Enzalutamide | 25 | 750 | $335,352.83 | โ |
| Gemtesa | Vibegron | 25 | 870 | $14,083.72 | โ |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | 1,172 | $859.37 | โ |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | 1,185 | $1,730.83 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 836 | $841.78 | 13 |
| Myrbetriq | Mirabegron | 16 | 690 | $10,016.26 | โ |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | 43 | $77.75 | 14 |
| Dutasteride | Dutasteride | 14 | 728 | $179.73 | โ |
(top 25 shown)
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2020-09-01NUCC Taxonomy Code: 208800000X
A urologist manages benign and malignant medical and surgical disorders of the genitourinary system and the adrenal gland. This specialist has comprehensive knowledge of and skills in endoscopic, percutaneous and open surgery of congenital and acquired conditions of the urinary and reproductive systems and their contiguous structures.
NUCC Taxonomy Code: 208800000X
A urologist manages benign and malignant medical and surgical disorders of the genitourinary system and the adrenal gland. This specialist has comprehensive knowledge of and skills in endoscopic, percutaneous and open surgery of congenital and acquired conditions of the urinary and reproductive systems and their contiguous structures.
Additional State Medicaid & Healthcare Payer Identifiers
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - UROLOGY
I20141215002564
WA
4880610609
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Medicare Group Practice Enrollments
Source: CMS Doctors and Clinicians National Downloadable File
Spokane Urology Pllc
1401 E Trent Ave, Spokane, WA 992022902
Phone: 5097473147
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Urology
Doctor of Medicine (M.D.)
Nurse Practitioner
Advanced Registered Nurse Practitioner
Urology
Doctor of Medicine (M.D.)
Urology
Doctor of Medicine (M.D.)
Nurse Practitioner - Family
Family Nurse Practitioner
Physician Assistant
Physician Assistant
Career & Practice History Timeline
Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status
Urology (license number reported to NPPES: VA 0101240091)
Urology (license number reported to NPPES: WA MD00039663)
Registered at 1401 E TRENT AVE STE 200, SPOKANE, WA 992022902 (Tel: 5097473147)
Registered at 1401 E TRENT AVE STE 200, SPOKANE, WA 992022902 (Tel: 5097473147)
Urology (license number reported to NPPES: VA 0101240091)
NPI status registered as active in NPPES database
Registered at 820 S MCCLELLAN ST, SUITE 118, SPOKANE, WA 992042457 (Tel: 5097473147)
Registered at 820 S MCCLELLAN ST, SUITE 118, SPOKANE, WA 992042457 (Tel: 5097473147)
Recorded as RAYMOND LANCE, M.D.
Urology (license number reported to NPPES: WA MD00039663)
First registered as active Individual Practitioner in NPPES Database.
NPI Administrative Meta
Other Urology Specialists in Spokane
- Dr. Shane Pearce, MD
- Dr. Bryan Voelzke, MD
- Dr. Duncan Sloan, MD
- Dr. Carl Walker, MD
- Dr. Robert Golden, MD
- Dr. Dirk Sypherd, MD
Mailing Address
1401 E Trent Ave Ste 200
Spokane, WA 992022902
Phone: 5097473147